Atlas Trials

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Clinical trial NCT01831726 · COMPLETED

Trial details

NCT number
NCT01831726
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Tumor Pathway Activations Inhibited by Dovitinib
Start date
2013-08-01
Primary completion
2015-12-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.